drugset / Trial / NCT02320812
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
Phase 1/2
Completed
28 enrolled
jCyte, Inc
California Institute for Regenerative Medicine (CIRM) · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.
Timeline
- Start
- 2015-06
- Primary completion
- 2017-07-19
- Completion
- 2017-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human retinal progenitor cells | Cell therapy | 500000 cells | Intravitreal |
| Subject | human retinal progenitor cells | Cell therapy | 1e+06 cells | Intravitreal |
| Subject | human retinal progenitor cells | Cell therapy | 2e+06 cells | Intravitreal |
| Subject | human retinal progenitor cells | Cell therapy | 3e+06 cells | Intravitreal |